BofA moved to No Rating on Avidity Biosciences (RNA) after the company announced that it has entered into an agreement to be acquired by Novartis (NVS) for about $12B, or $72 per share. Given the deal, the stock is no longer trading on fundamentals, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA: